Tag: NASDAQ:BCLI

December 2, 2019

Top 10 Stem Cell Companies On The NASDAQ

The global stem cell therapy market is expected to grow at a CAGR of 36.52 percent between 2017 and 2021....
October 7, 2019

BrainStorm Receives US Patent Allowance for NurOwn Platform

The company received a notice of allowance for its US Patent Application called 'Method of Qualifying Cells.'
January 22, 2019

BrainStorm Granted Additional Patent for NurOwn in Israel

BrainStorm Cell Therapeutics (NASDAQ:BCLI), a leader in developing innovative autologous cellular therapies for debilitating neurodegenerative diseases, today announced that the...
January 18, 2019

This is the Year for NurOwn’s Stem Cell Phase 3 ALS Development

Brainstorm Cell Therapeutics' management team discusses an ongoing ALS Phase 3 clinical trial, the company's technology and more.
January 7, 2019

Notes from the Floor: Biotech Showcase, Day 1

The Biotech Showcase takes place in San Francisco from January 7 to 9. Here's what went on during the conference...
December 17, 2018

FDA Accepts BrainStorm’s NurOwn IND Application for Progressive Multiple Sclerosis

BrainStorm Cell Therapeutics (NASDAQ:BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases, announced that the...
December 10, 2018

5 Top Biotech News Stories of 2018

The Investing News Network recaps 2018 with the five top biotech news stories of the year, according to our readers.